Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status

Thomas E. Stinchcombe, Jaeun Choi, Michael J. Schell, Andrea Mears, Paul E. Jones, Robert V. Nachtsheim, Mark A. Socinski

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Poor performance status patients with advanced non-small cell lung cancer (NSCLC) have frequently been excluded from clinical trials due to the perception that they would have excessive treatment-related toxicity and a limited life expectancy. Methods: A retrospective review of two multicenter trials centered at the University of North Carolina of patients who were treated with platinum-based chemotherapy for advanced NSCLC was conducted. Patients were divided into two subgroups based on Karnofsky performance status (KPS). Patients with a KPS = 70 were considered to have poor performance status, while patients with a KPS ≥80 were considered to have good performance status. Results: Of the 387 patients, 19% (n = 73) had a poor performance status. The response rate (complete and partial responses) was similar between the two sub-groups (26% versus 28%); however, there was a difference in survival (p = 0.0004, log-rank test) between the groups. The median survival and 1-year survival rate for the poor performance status patients was 4.9 months and 21%, while the good performance status patients had a median survival of 8.4 months and a 1-year survival rate of 31%. The rate of National Cancer Institute (NCI) Common Toxicity Criteria (CTC) toxicities was similar between the two groups (p = 0.33). The percentage of patients receiving <4 cycles of therapy in the poor and good performance status was 55 and 39%, respectively (p = 0.012). Conclusions: Patients with poor performance status treated with platinum based chemotherapy have a similar rate of toxicity compared to good performance status patients. Their overall survival was lower despite a similar response to chemotherapy.

Original languageEnglish (US)
Pages (from-to)237-243
Number of pages7
JournalLung Cancer
Volume51
Issue number2
DOIs
StatePublished - Feb 2006
Externally publishedYes

Fingerprint

Carboplatin
Non-Small Cell Lung Carcinoma
Drug Therapy
Karnofsky Performance Status
Survival
Platinum
Survival Rate
National Cancer Institute (U.S.)
Life Expectancy
Multicenter Studies
Clinical Trials

Keywords

  • Chemotherapy
  • Non-small cell lung cancer (NSCLC)
  • Performance status (PS)
  • Platinum
  • Poor performance status
  • Toxicity

ASJC Scopus subject areas

  • Oncology

Cite this

Stinchcombe, T. E., Choi, J., Schell, M. J., Mears, A., Jones, P. E., Nachtsheim, R. V., & Socinski, M. A. (2006). Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status. Lung Cancer, 51(2), 237-243. https://doi.org/10.1016/j.lungcan.2005.10.018

Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status. / Stinchcombe, Thomas E.; Choi, Jaeun; Schell, Michael J.; Mears, Andrea; Jones, Paul E.; Nachtsheim, Robert V.; Socinski, Mark A.

In: Lung Cancer, Vol. 51, No. 2, 02.2006, p. 237-243.

Research output: Contribution to journalArticle

Stinchcombe, TE, Choi, J, Schell, MJ, Mears, A, Jones, PE, Nachtsheim, RV & Socinski, MA 2006, 'Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status', Lung Cancer, vol. 51, no. 2, pp. 237-243. https://doi.org/10.1016/j.lungcan.2005.10.018
Stinchcombe, Thomas E. ; Choi, Jaeun ; Schell, Michael J. ; Mears, Andrea ; Jones, Paul E. ; Nachtsheim, Robert V. ; Socinski, Mark A. / Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status. In: Lung Cancer. 2006 ; Vol. 51, No. 2. pp. 237-243.
@article{cc284546692c448d8557475c0e0b133d,
title = "Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status",
abstract = "Background: Poor performance status patients with advanced non-small cell lung cancer (NSCLC) have frequently been excluded from clinical trials due to the perception that they would have excessive treatment-related toxicity and a limited life expectancy. Methods: A retrospective review of two multicenter trials centered at the University of North Carolina of patients who were treated with platinum-based chemotherapy for advanced NSCLC was conducted. Patients were divided into two subgroups based on Karnofsky performance status (KPS). Patients with a KPS = 70 were considered to have poor performance status, while patients with a KPS ≥80 were considered to have good performance status. Results: Of the 387 patients, 19{\%} (n = 73) had a poor performance status. The response rate (complete and partial responses) was similar between the two sub-groups (26{\%} versus 28{\%}); however, there was a difference in survival (p = 0.0004, log-rank test) between the groups. The median survival and 1-year survival rate for the poor performance status patients was 4.9 months and 21{\%}, while the good performance status patients had a median survival of 8.4 months and a 1-year survival rate of 31{\%}. The rate of National Cancer Institute (NCI) Common Toxicity Criteria (CTC) toxicities was similar between the two groups (p = 0.33). The percentage of patients receiving <4 cycles of therapy in the poor and good performance status was 55 and 39{\%}, respectively (p = 0.012). Conclusions: Patients with poor performance status treated with platinum based chemotherapy have a similar rate of toxicity compared to good performance status patients. Their overall survival was lower despite a similar response to chemotherapy.",
keywords = "Chemotherapy, Non-small cell lung cancer (NSCLC), Performance status (PS), Platinum, Poor performance status, Toxicity",
author = "Stinchcombe, {Thomas E.} and Jaeun Choi and Schell, {Michael J.} and Andrea Mears and Jones, {Paul E.} and Nachtsheim, {Robert V.} and Socinski, {Mark A.}",
year = "2006",
month = "2",
doi = "10.1016/j.lungcan.2005.10.018",
language = "English (US)",
volume = "51",
pages = "237--243",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status

AU - Stinchcombe, Thomas E.

AU - Choi, Jaeun

AU - Schell, Michael J.

AU - Mears, Andrea

AU - Jones, Paul E.

AU - Nachtsheim, Robert V.

AU - Socinski, Mark A.

PY - 2006/2

Y1 - 2006/2

N2 - Background: Poor performance status patients with advanced non-small cell lung cancer (NSCLC) have frequently been excluded from clinical trials due to the perception that they would have excessive treatment-related toxicity and a limited life expectancy. Methods: A retrospective review of two multicenter trials centered at the University of North Carolina of patients who were treated with platinum-based chemotherapy for advanced NSCLC was conducted. Patients were divided into two subgroups based on Karnofsky performance status (KPS). Patients with a KPS = 70 were considered to have poor performance status, while patients with a KPS ≥80 were considered to have good performance status. Results: Of the 387 patients, 19% (n = 73) had a poor performance status. The response rate (complete and partial responses) was similar between the two sub-groups (26% versus 28%); however, there was a difference in survival (p = 0.0004, log-rank test) between the groups. The median survival and 1-year survival rate for the poor performance status patients was 4.9 months and 21%, while the good performance status patients had a median survival of 8.4 months and a 1-year survival rate of 31%. The rate of National Cancer Institute (NCI) Common Toxicity Criteria (CTC) toxicities was similar between the two groups (p = 0.33). The percentage of patients receiving <4 cycles of therapy in the poor and good performance status was 55 and 39%, respectively (p = 0.012). Conclusions: Patients with poor performance status treated with platinum based chemotherapy have a similar rate of toxicity compared to good performance status patients. Their overall survival was lower despite a similar response to chemotherapy.

AB - Background: Poor performance status patients with advanced non-small cell lung cancer (NSCLC) have frequently been excluded from clinical trials due to the perception that they would have excessive treatment-related toxicity and a limited life expectancy. Methods: A retrospective review of two multicenter trials centered at the University of North Carolina of patients who were treated with platinum-based chemotherapy for advanced NSCLC was conducted. Patients were divided into two subgroups based on Karnofsky performance status (KPS). Patients with a KPS = 70 were considered to have poor performance status, while patients with a KPS ≥80 were considered to have good performance status. Results: Of the 387 patients, 19% (n = 73) had a poor performance status. The response rate (complete and partial responses) was similar between the two sub-groups (26% versus 28%); however, there was a difference in survival (p = 0.0004, log-rank test) between the groups. The median survival and 1-year survival rate for the poor performance status patients was 4.9 months and 21%, while the good performance status patients had a median survival of 8.4 months and a 1-year survival rate of 31%. The rate of National Cancer Institute (NCI) Common Toxicity Criteria (CTC) toxicities was similar between the two groups (p = 0.33). The percentage of patients receiving <4 cycles of therapy in the poor and good performance status was 55 and 39%, respectively (p = 0.012). Conclusions: Patients with poor performance status treated with platinum based chemotherapy have a similar rate of toxicity compared to good performance status patients. Their overall survival was lower despite a similar response to chemotherapy.

KW - Chemotherapy

KW - Non-small cell lung cancer (NSCLC)

KW - Performance status (PS)

KW - Platinum

KW - Poor performance status

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=31444438647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31444438647&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2005.10.018

DO - 10.1016/j.lungcan.2005.10.018

M3 - Article

C2 - 16378657

AN - SCOPUS:31444438647

VL - 51

SP - 237

EP - 243

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -